Amili Pte. Ltd. is Southeast Asia's first precision gut microbiome company, headquartered in Singapore. Founded in 2019, Amili is dedicated to advancing the understanding of the human gut microbiome and its impact on health, particularly within diverse Asian populations. The company builds the region's largest multi-ethnic microbiome database, offers microbiome testing services (including direct-to-consumer kits like BIO & ME), conducts research, and develops data-driven interventions and personalized probiotics (like GENIE). Amili collaborates with academic institutions, healthcare providers, and industry partners to translate microbiome science into tangible health outcomes, focusing on diagnostics, predictive analytics, and therapeutic applications to address various health conditions.
Serves as the central hub for Amili's research and development, clinical diagnostics, data science operations, strategic planning, and business development activities.
Strategically located within the National University Hospital (NUH) Medical Centre, facilitating close collaborations with leading medical researchers and clinicians. The facility is equipped with advanced laboratories for microbiome sequencing and analysis.
A dynamic, science-driven, and innovative environment. The culture fosters collaboration, continuous learning, and a strong sense of purpose aimed at improving health outcomes across Asia. Employees are typically passionate about biotechnology and personalized medicine.
The Singapore headquarters leverages the nation's robust research infrastructure, access to diverse talent, strong government support for biotech, and a strategic position to serve the broader Southeast Asian market.
Amili Pte. Ltd. has a primary focus on Southeast Asia, with established offices in Singapore and Malaysia. The company also has a significant presence and partnerships in Thailand, Indonesia, and India, with ongoing efforts to expand into Greater China. Globally, Amili supports functions such as building the world's largest multi-ethnic Asian gut microbiome databank, providing clinical diagnostics and direct-to-consumer testing, fostering international research collaborations, and developing microbiome-based health products tailored for diverse Asian populations.
1 Medical Drive, #05-02, National University Hospital (NUH) Medical Centre
Singapore
Singapore
Singapore
Address: Level 28, G Tower, 199 Jalan Tun Razak, 50400 Kuala Lumpur
To expand Amili's reach in the Malaysian market, cater to the local demand for personalized gut health solutions, and contribute to the company's regional microbiome data collection efforts.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, AMILI ' leadership includes:
AMILI has been backed by several prominent investors over the years, including:
As of late 2023/early 2024, there have been no major publicly announced executive new hires or departures at Amili Pte. Ltd. The founding executive team continues to spearhead the company's growth and strategic initiatives.
Discover the tools AMILI uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Amili Pte. Ltd. appears to use a straightforward email format based on employee first names. This is a common practice for many modern tech and biotech companies.
[first_name]@amili.asia
Format
jeremy@amili.asia
Example
85%
Success rate
MobiHealthNews • November 21, 2023
Singapore-based microbiome company Amili has rolled out a direct-to-consumer gut health test kit. Called BIO & ME, the home test kit is now available in Singapore and Malaysia with plans for expansion to Thailand and Indonesia....more
BioSpectrum Asia • February 22, 2023
Amili, Southeast Asia's first precision gut microbiome company, has announced its strategic partnership with Osstem Pharma, a leading South Korean pharmaceutical company. This collaboration marks Amili’s entry into the South Korean market with its personalised probiotics line, GENIE....more
TechCrunch • June 7, 2022
Singapore-based Amili, Southeast Asia’s first precision gut microbiome company, announced today it has raised a $10.5 million Series A. The round was led by Vulcan Capital, the multi-billion-dollar investment arm of the late Microsoft co-founder Paul G. Allen, with participation from Pruksa Group, TVM Capital Healthcare and others....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including AMILI , are just a search away.